Strategies to Reduce the Risks of MRNA Drug and Vaccine Toxicity

Overview

Journal Nat Rev Drug Discov

Specialty Pharmacology

Date 2024 Jan 24

PMID 38263456

Authors

Dimitrios Bitounis

Eric Jacquinet

Maximillian A Rogers

Mansoor M Amiji

Affiliations

Soon will be listed here.

Abstract

mRNA formulated with lipid nanoparticles is a transformative technology that has enabled the rapid development and administration of billions of coronavirus disease 2019 (COVID-19) vaccine doses worldwide. However, avoiding unacceptable toxicity with mRNA drugs and vaccines presents challenges. Lipid nanoparticle structural components, production methods, route of administration and proteins produced from complexed mRNAs all present toxicity concerns. Here, we discuss these concerns, specifically how cell tropism and tissue distribution of mRNA and lipid nanoparticles can lead to toxicity, and their possible reactogenicity. We focus on adverse events from mRNA applications for protein replacement and gene editing therapies as well as vaccines, tracing common biochemical and cellular pathways. The potential and limitations of existing models and tools used to screen for on-target efficacy and de-risk off-target toxicity, including in vivo and next-generation in vitro models, are also discussed.

Citing Articles

Developing mRNA Nanomedicines with Advanced Targeting Functions.

Wang J, Cai L, Li N, Luo Z, Ren H, Zhang B Nanomicro Lett. 2025; 17(1):155.

PMID: 39979495 PMC: 11842722. DOI: 10.1007/s40820-025-01665-9.

Nanoparticle-Mediated mRNA Delivery to Triple-Negative Breast Cancer (TNBC) Patient-Derived Xenograft (PDX) Tumors.

El-Sahli S, Manturthi S, Durocher E, Bo Y, Akman A, Sannan C ACS Pharmacol Transl Sci. 2025; 8(2):460-469.

PMID: 39974646 PMC: 11833720. DOI: 10.1021/acsptsci.4c00597.

High-Throughput Quantification and Characterization of Dual Payload mRNA/LNP Cargo via Deformulating Size Exclusion and Ion Pairing Reversed Phase Assays.

Imiolek M, Cojocaru R, Fekete S, Le Huray J, Lauber M Anal Chem. 2025; 97(5):3091-3098.

PMID: 39883007 PMC: 11822733. DOI: 10.1021/acs.analchem.4c06296.

A Novel Approach for In Vitro Testing and Hazard Evaluation of Nanoformulated RyR2-Targeting siRNA Drugs Using Human PBMCs.

Bettinsoli V, Melzi G, Crea A, Degli Esposti L, Iafisco M, Catalucci D Life (Basel). 2025; 15(1).

PMID: 39860035 PMC: 11766699. DOI: 10.3390/life15010095.

Multivalent ionizable lipid-polypeptides for tumor-confined mRNA transfection.

Zhao X, Zhang Y, Wang X, Fu Z, Zhong Z, Deng C Bioact Mater. 2025; 46():423-433.

PMID: 39850023 PMC: 11754973. DOI: 10.1016/j.bioactmat.2024.12.032.

References

Barouch D . Covid-19 Vaccines - Immunity, Variants, Boosters. N Engl J Med. 2022; 387(11):1011-1020. PMC: 9454645. DOI: 10.1056/NEJMra2206573. View

El Sahly H, Baden L, Essink B, Doblecki-Lewis S, Martin J, Anderson E . Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med. 2021; 385(19):1774-1785. PMC: 8482810. DOI: 10.1056/NEJMoa2113017. View

Thomas S, Perez J, Lockhart S, Hariharan S, Kitchin N, Bailey R . Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial. Vaccine. 2022; 40(10):1483-1492. PMC: 8702495. DOI: 10.1016/j.vaccine.2021.12.046. View

Rouf N, Biswas S, Tarannum N, Oishee L, Muna M . Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases. RNA Biol. 2022; 19(1):386-410. PMC: 8973339. DOI: 10.1080/15476286.2022.2055923. View

Chalkias S, Harper C, Vrbicky K, Walsh S, Essink B, Brosz A . A Bivalent Omicron-Containing Booster Vaccine against Covid-19. N Engl J Med. 2022; 387(14):1279-1291. PMC: 9511634. DOI: 10.1056/NEJMoa2208343. View

Verma M, Ozer I, Xie W, Gallagher R, Teixeira A, Choy M . The landscape for lipid-nanoparticle-based genomic medicines. Nat Rev Drug Discov. 2023; 22(5):349-350. DOI: 10.1038/d41573-023-00002-2. View

Ingber D . Human organs-on-chips for disease modelling, drug development and personalized medicine. Nat Rev Genet. 2022; 23(8):467-491. PMC: 8951665. DOI: 10.1038/s41576-022-00466-9. View

Granot Y, Peer D . Delivering the right message: Challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics-An innate immune system standpoint. Semin Immunol. 2017; 34:68-77. DOI: 10.1016/j.smim.2017.08.015. View

Duan Q, Hu T, Zhu Q, Jin X, Chi F, Chen X . How far are the new wave of mRNA drugs from us? mRNA product current perspective and future development. Front Immunol. 2022; 13:974433. PMC: 9510989. DOI: 10.3389/fimmu.2022.974433. View

10.

Igyarto B, Jacobsen S, Ndeupen S . Future considerations for the mRNA-lipid nanoparticle vaccine platform. Curr Opin Virol. 2021; 48:65-72. PMC: 8065267. DOI: 10.1016/j.coviro.2021.03.008. View

11.

Moein Moghimi S, Simberg D . Pro-inflammatory concerns with lipid nanoparticles. Mol Ther. 2022; 30(6):2109-2110. PMC: 9047613. DOI: 10.1016/j.ymthe.2022.04.011. View

12.

Kenjo E, Hozumi H, Makita Y, Iwabuchi K, Fujimoto N, Matsumoto S . Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice. Nat Commun. 2021; 12(1):7101. PMC: 8654819. DOI: 10.1038/s41467-021-26714-w. View

13.

Guerrini G, Gioria S, Sauer A, Lucchesi S, Montagnani F, Pastore G . Monitoring Anti-PEG Antibodies Level upon Repeated Lipid Nanoparticle-Based COVID-19 Vaccine Administration. Int J Mol Sci. 2022; 23(16). PMC: 9408675. DOI: 10.3390/ijms23168838. View

14.

Verbeke R, Hogan M, Lore K, Pardi N . Innate immune mechanisms of mRNA vaccines. Immunity. 2022; 55(11):1993-2005. PMC: 9641982. DOI: 10.1016/j.immuni.2022.10.014. View

15.

Tenchov R, Bird R, Curtze A, Zhou Q . Lipid Nanoparticles─From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement. ACS Nano. 2021; 15(11):16982-17015. DOI: 10.1021/acsnano.1c04996. View

16.

Li D, Liu C, Li Y, Tenchov R, Sasso J, Zhang D . Messenger RNA-Based Therapeutics and Vaccines: What's beyond COVID-19?. ACS Pharmacol Transl Sci. 2023; 6(7):943-969. PMC: 10353067. DOI: 10.1021/acsptsci.3c00047. View

17.

Huang X, Kong N, Zhang X, Cao Y, Langer R, Tao W . The landscape of mRNA nanomedicine. Nat Med. 2022; 28(11):2273-2287. DOI: 10.1038/s41591-022-02061-1. View

18.

Alexopoulou L, Holt A, Medzhitov R, Flavell R . Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001; 413(6857):732-8. DOI: 10.1038/35099560. View

19.

Kariko K, Ni H, Capodici J, Lamphier M, Weissman D . mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem. 2004; 279(13):12542-50. DOI: 10.1074/jbc.M310175200. View

20.

Panda D, Gjinaj E, Bachu M, Squire E, Novatt H, Ozato K . IRF1 Maintains Optimal Constitutive Expression of Antiviral Genes and Regulates the Early Antiviral Response. Front Immunol. 2019; 10:1019. PMC: 6529937. DOI: 10.3389/fimmu.2019.01019. View